Skip to main content
. 2023 Jan 27;9(4):eabq3104. doi: 10.1126/sciadv.abq3104

Fig. 4. Safety assessment of FCS.

Fig. 4.

(A) Representative images of OCT of cornea treated with PBS, FCS, CS, or SDS eyedrops for 2 or 4 weeks (scale bar, 200 μm). (B) Representative images of fluorescein cornea staining of mouse eyes by slit-lamp microscopy treated with PBS, FCS, CS, or SDS eyedrops for 2 or 4 weeks (scale bar, 1 mm). (C) Statistical analysis of corneal thickness according to the OCT images. (D and E) Representative ERG waves of mouse eyes treated with PBS, FCS, CS, or SDS eyedrops for 4 weeks and statistical analysis of A waves and B waves. (F) Statistical analysis of retinal thickness treated with PBS, FCS, CS, or SDS eyedrops for 2 or 4 weeks. (G) Statistical analysis of IOPs of eyes in mice treated with PBS, SDS, CS, and FCS eyedrops on week 2 or week 4. (H) TUNEL staining of corneal tissues of mice treated with PBS, SDS, CS, and FCS eyedrops for 4 weeks (scale bar, 200 μm). Data were represented as means ± SD. P values in (E) were calculated by using one-way ANOVA (****P < 0.0001).